Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT04359134
Other study ID # Neo-POLM
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date March 10, 2020
Est. completion date April 5, 2022

Study information

Verified date July 2021
Source IRCCS Azienda Ospedaliero-Universitaria di Bologna
Contact Silvia Galletti
Phone 0039 051 2144774
Email silvia.galletti4@unibo.it
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

Respiratory distress syndrome (RDS) is among the most common complications of preterm birth, and typically becomes manifested soon after birth. A failure of the rapid reuptake of fetal lung fluids after birth, with subsequent liquid retention in the alveolar space, together with the deficit of surfactant proteins ensuing from lung immaturity represent the leading mechanisms for the development of RDS, which may require different levels of respiratory support. An increasingly used method for the evaluation of the neonatal lung is pulmonary ultrasound, which allows assessing alveolar fluids and other pathological conditions in a non-invasive manner, and has been shown to predict the need for respiratory support and for surfactant administration in preterm infants with RDS. However, this method requires specific training, is operator-dependent and does not provide a trend able assessment over time. Transthoracic electrical bioimpedance (TEB) allows continuous and non-invasive monitoring of static and dynamic thoracic fluids. It has been recently introduced in neonatal clinical practice to assess such hemodynamic parameters as cardiac output and also quantifies static thoracic fluids contents (TFC). This method provides continuous and non-operator dependent data on the pulmonary fluid status over time and does not require specific training. The combination of lung ultrasound with TEB could open to new diagnostic and prognostic perspectives in preterm infants with RDS.


Description:

Introduction Respiratory distress syndrome (RDS) is among the most common complications of preterm birth, and typically becomes manifested soon after birth. The rapid reuptake of fetal lung fluids plays an important role in transitional events at birth. Most of this fluid is reabsorbed through epithelial alveolar cells by an active sodium transporter. Mechanical events play a role in this exchange too. A failure of the rapid reuptake of fetal lung fluids after birth, with subsequent liquid retention in the alveolar space, together with the deficit of surfactant proteins ensuing from lung immaturity represent the leading mechanisms for the development of RDS, which may require different levels of respiratory support, ranging from mechanical ventilation to less invasive modalities (nasal cannulas or continuous positive airway pressure (CPAP)). An increasingly used method for lung evaluation in the newborn is lung ultrasound, which allows to evaluate the alveolar fluid and to differentiate among several pathological conditions (transient tachypnea of the newborn, meconium aspiration, respiratory distress syndrome, pneumothorax, and pleural effusion) and, in the preterm population, has also been proved to predict of the need for respiratory support and for surfactant administration. Compared to traditional radiological assessments, this non-invasive technique does not imply the use of X-ray; however, it requires specific training, it is operator-dependent and does not allow a continuous and trend able evaluation over time, but only serial assessments. Transthoracic electrical bioimpedance (TEB) allows continuous, non-invasive and real-time monitoring of static and dynamic thoracic fluids. It has been recently introduced in neonatal clinical practice to monitor such hemodynamic parameters as cardiac output, providing useful clinical information in hospitalized preterm infants, or neonates undergoing hemodynamic procedures. This technique allows quantifying static thoracic fluid contents (TFC) in a non-invasive and continuous manner. Compared to ultrasound, this method provides continuous and non-operator dependent data on the lung fluid status over time and does not require specific training for its use and interpretation. Current literature reported a significant correlation between TFC values and respiratory distress, but, to date, it has not been investigated whether this parameter may predict RDS evolution, or if it is influenced by specific neonatal characteristics associated with pulmonary overflow, such as the presence of a patent ductus arteriosus (PDA), which is a common finding over the transitional period, defined as the first 72 hours of life. Combining lung ultrasound to transthoracic electrical bioimpedance could open to new diagnostic and prognostic perspectives in preterm infants with RDS during the first days of life. Objectives: 1. To evaluate the correlation between TFC, measured by transthoracic electrical bioimpedance (TEB), and a pulmonary ultrasound score, used for the evaluation of lung fluids in preterm infants with RDS in the Neonatal Intensive Care Unit. 2. To assess whether the combination of TFC with a pulmonary ultrasound score can be predictive of RDS evolution over the next 24 hours (need for surfactant, need for mechanical ventilation vs. suspension of ventilatory support). 3. Evaluation of pulmonary ultrasound score, TFC levels and left cardiac output in relation to the status of the ductus arteriosus (hemodynamically significant, restrictive or closed). Methods: Infants born at S. Orsola-Malpighi Hospital and Niguarda Hospital and admitted to the local Neonatal Intensive Care Units are consecutively enrolled in this observational prospective study if fulfilling the following eligibility criteria: gestational age ≤34 weeks' gestation, diagnosis of respiratory distress (defined by the need for respiratory support with nasal cannulas, nasal CPAP or mechanical ventilation), 0-24 hours of life, written informed consent obtained from parents/legal guardians of each infant. The following conditions are considered as exclusion criteria: main congenital malformation, including congenital heart disease, meconium aspiration, pneumothorax, perinatal asphyxia/hypoxic-ischemic encephalopathy, concomitant use of experimental dugs. Enrolled infants undergo serial lung and cardiac ultrasound evaluations at 0-24 (V1), at 24-48 (V2) and at 48-72 (V3)hours of life. A simultaneous evaluation of hemodynamic parameters and TFC by means of TEB is also performed. Lung ultrasound findings are classified according to a validated pulmonary ultrasound score that takes into account six pulmonary fields (right upper anterior, right lower anterior, right lateral, left upper anterior, left lower anterior, left lateral). For each field a number is assigned: - 0: only A lines or <3 B lines - 1: ≥3 B lines - 2: crowded and confluent B lines with or without consolidations - 3: important consolidation If at 72 hours of life a hemodynamically relevant patent ductus arteriosus is still evident at cardiac ultrasound, the ultrasound and TEB monitoring are carried on until PDA closure. Outcome: need for surfactant administration (and number of surfactant administrations), inhaled oxygen fraction, need for diuretic therapy, duration of ventilatory support with nasal canula/nasal CPAP/mechanical ventilation, duration of oxygen therapy, bronchopulmonary dysplasia at 36 weeks, duration of hospitalization and time for reach total enteral nutrition. Statistic analysis: SPSS will be used for the statistical analysis. The diagnostic accuracy of TFC and of the ultrasound score for predicting the need for ventilatory support and for surfactant administration will be evaluated by area under ROC curve in order to find the optimal cut off value. The cardiac output values will be analyzed in relation to the state of the ductus arteriosus with Kruskal-Wallis test and included in a multivariate model in order to rule out the influence of confounding factors (for example the modality of ventilatory support). Significance level is set at p<0,05.


Recruitment information / eligibility

Status Recruiting
Enrollment 60
Est. completion date April 5, 2022
Est. primary completion date March 31, 2022
Accepts healthy volunteers
Gender All
Age group N/A to 7 Days
Eligibility Inclusion Criteria: - 0-24 hours of life, - gestational age =34 weeks' gestation - diagnosis of respiratory distress - written informed consent obtained from parents/legal guardians of each infant. Exclusion Criteria: - major congenital malformations, including congenital heart disease - meconium aspiration - pneumothorax - perinatal asphyxia/hypoxic-ischemic encephalopathy - concomitant use of experimental drugs

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
Italy S. Orsola-Malpighi University Hospital Bologna Emilia-Romagna
Italy Niguarda Hospital Milano

Sponsors (2)

Lead Sponsor Collaborator
IRCCS Azienda Ospedaliero-Universitaria di Bologna Niguarda Hospital

Country where clinical trial is conducted

Italy, 

Outcome

Type Measure Description Time frame Safety issue
Primary Correlation between lung ultrasound score and RDS evolution Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 0-24 hours of life
Primary Correlation between lung ultrasound score and RDS evolution Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 24-48 hours of life
Primary Correlation between lung ultrasound score and RDS evolution Pearson correlation analysis between the score of lung ultrasound and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 48-72 hours of life
Primary Correlation between TFC and RDS evolution Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 0-24 hours of life
Primary Correlation between TFC and RDS evolution Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 24-48 hours of life
Primary Correlation between TFC and RDS evolution Pearson correlation analysis between TFC values and RDS evolution over the next 24 hours (defined by the need for surfactant or a step-up in the type of respiratory support). 48-72 hours of life
Primary Correlation between TFC and lung ultrasound score Pearson correlation analysis between TFC values and lung ultrasound score 0-24 hours of life
Primary Correlation between TFC and lung ultrasound score Pearson correlation analysis between TFC values and lung ultrasound score 24-48 hours of life
Primary Correlation between TFC and lung ultrasound score Pearson correlation analysis between TFC values and lung ultrasound score 48-72 hours of life
Secondary Changes in TFC values and lung ultrasound score between time periods with patent and closed ductus arteriosus Changes in TFC and lung ultrasound scores between time periods with patent and closed ductus arteriosus 0-72 hours of life
See also
  Status Clinical Trial Phase
Recruiting NCT04016246 - Respiratory Effect of the LISA Method With Sedation by Propofol Versus Absence of Sedation. Phase 3
Enrolling by invitation NCT04118400 - Ventilator Weaning Outcome Between NIV-NAVA and Nasal CPAP (or IMV ) Modes in Premature Neonates
Completed NCT01941745 - Efficacy of Recombinant Human Clara Cell 10 Protein (rhCC10) Administered to Premature Neonates With Respiratory Distress Syndrome Phase 2
Not yet recruiting NCT04019106 - Budesonide With Intratracheal Surfactants in Extremely Preterm Infants Phase 1/Phase 2
Not yet recruiting NCT04862377 - Intratracheal Budesonide With Surfactant to Prevent Bronchopulmmonary Dysplasia. Phase 3
Not yet recruiting NCT05791331 - REspiratory MEchanics for Delivering Individualised Exogenous Surfactant N/A
Completed NCT04086095 - Feasibility Study - Neofact N/A
Not yet recruiting NCT05609877 - The NONA-LISA Trial N/A
Recruiting NCT04326270 - Crossover Comparison of Tidal Volume Delivery During Nasal Intermittent Positive Pressure Ventilation in Preterm Infants: Infant Cannula vs. Nasal Continuous Positive Airway Pressure Prongs N/A
Active, not recruiting NCT03969992 - A Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AeroFact Phase 2
Completed NCT03700606 - Physiological Changes With High-Flow Nasal Cannula N/A
Not yet recruiting NCT06229821 - Safety and Efficacy of Intrapulmonary Percussive Ventilation in Preterm Infants N/A
Recruiting NCT05446389 - PAL to Improve Oral Feeding for Infants With Chronic Lung Disease N/A
Withdrawn NCT04914715 - nHFOV Versus Invasive Conventional Ventilation for Preterm Neonates With Respiratory Distress Syndrome N/A
Recruiting NCT03825835 - 30% or 60% Oxygen at Birth to Improve Neurodevelopmental Outcomes in Very Low Birthweight Infants N/A
Recruiting NCT03562182 - Effect of Steroid Administration on Maternal Blood Levels of hLPCAT1 mRNA
Completed NCT05031650 - Open Lung Strategy During Non-Invasive Respiratory Support of Very Preterm Infants in the Delivery Room N/A
Completed NCT03306524 - The Role of Circuit Flow During Mechanical Ventilation of Neonates N/A
Completed NCT01473264 - Safety, Pk and Anti-inflammatory Effects of CC10 Protein in Premature Infants With Respiratory Distress Syndrome (RDS) Phase 1/Phase 2
Completed NCT03548324 - Enteral Nutrition Tolerance And REspiratory Support (ENTARES) N/A